These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 17386127)

  • 21. Of mice and (wo)men: is this any way to test a new drug?
    Haddad TC; Yee D
    J Clin Oncol; 2008 Feb; 26(6):830-2. PubMed ID: 18281652
    [No Abstract]   [Full Text] [Related]  

  • 22. Are volumetric changes of brain metastases the best evaluation of efficacy?
    Belkacémi Y; Kuten A
    J Clin Oncol; 2008 Nov; 26(31):5137-8; author reply 5138-9. PubMed ID: 18838700
    [No Abstract]   [Full Text] [Related]  

  • 23. Better treatments needed for breast cancer brain metastases.
    Lin NU
    Lancet Oncol; 2015 Dec; 16(16):1583-4. PubMed ID: 26596673
    [No Abstract]   [Full Text] [Related]  

  • 24. Neratinib Graduates to I-SPY 3.
    Cancer Discov; 2014 Jun; 4(6):624. PubMed ID: 24891343
    [No Abstract]   [Full Text] [Related]  

  • 25. [Oncology 2010].
    Wörmann B
    Dtsch Med Wochenschr; 2010 Jun; 135(25-26):1339-40. PubMed ID: 20556695
    [No Abstract]   [Full Text] [Related]  

  • 26. Mathematics in the realm of lapatinib: 500 + 500 = 1,500?
    Seruga B; Tannock IF
    J Clin Oncol; 2008 Jun; 26(18):2940-2. PubMed ID: 18458041
    [No Abstract]   [Full Text] [Related]  

  • 27. Ten remarkable years.
    Sledge GW
    Clin Breast Cancer; 2010 Jun; 10(3):178. PubMed ID: 20497915
    [No Abstract]   [Full Text] [Related]  

  • 28. Management of Neutropenic Toxicity From CDK4/6 Inhibitors.
    Frinzi Byers K
    Oncology (Williston Park); 2019 Jan; 33(1):26-7. PubMed ID: 30731015
    [No Abstract]   [Full Text] [Related]  

  • 29. Two targets, one drug for new EGFR inhibitors.
    McNeil C
    J Natl Cancer Inst; 2006 Aug; 98(16):1102-3. PubMed ID: 16912259
    [No Abstract]   [Full Text] [Related]  

  • 30. Palbociclib (Ibrance) for metastatic breast cancer.
    Med Lett Drugs Ther; 2015 Aug; 57(1475):115-6. PubMed ID: 26262882
    [No Abstract]   [Full Text] [Related]  

  • 31. Inhibition of receptor tyrosine kinases in combination with chemotherapy for the treatment of breast cancer.
    Moulder SL; Craft BS; Hortobagyi GN
    Anticancer Agents Med Chem; 2008 Jun; 8(5):481-7. PubMed ID: 18537531
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Chemotherapy and targeted drugs to reinforce each other].
    Foukakis T; Bergh J
    Lakartidningen; 2017 Feb; 114():. PubMed ID: 28221400
    [No Abstract]   [Full Text] [Related]  

  • 33. [Pharmacological profiles and clinical effects of lapatinib tosilate (Tykerb)].
    Arai H; Yamaki M; Nishimura Y
    Nihon Yakurigaku Zasshi; 2010 Sep; 136(3):175-84. PubMed ID: 20838021
    [No Abstract]   [Full Text] [Related]  

  • 34. Lapatinib for inflammatory breast cancer.
    Hall PS; Hanby A; Cameron DA
    Lancet Oncol; 2009 Jun; 10(6):538-9. PubMed ID: 19482243
    [No Abstract]   [Full Text] [Related]  

  • 35. 'Small' randomised neo-adjuvant chemotherapy trials in breast cancer reporting on pathological response: more harm than good?
    Bonnefoi H
    Ann Oncol; 2005 Sep; 16(9):1407-10. PubMed ID: 16076932
    [No Abstract]   [Full Text] [Related]  

  • 36. Open randomized trials in the management of primary breast cancer.
    Stewart HJ
    Eur J Surg Oncol; 1995 Jun; 21(3):233-7. PubMed ID: 7781786
    [No Abstract]   [Full Text] [Related]  

  • 37. Synergistic molecular mechanisms in hormone-sensitive breast cancer.
    Cussac AL
    Adv Exp Med Biol; 2006; 587():375-86. PubMed ID: 17163177
    [No Abstract]   [Full Text] [Related]  

  • 38. The use of CDK 4/6 inhibitors in the adjuvant treatment of breast cancer: Timing matters.
    Guven DC; Sahin TK; Aksoy S
    Breast J; 2020 Dec; 26(12):2435-2436. PubMed ID: 32812288
    [No Abstract]   [Full Text] [Related]  

  • 39. Reversal of multidrug resistance in breast cancer: many more open questions than answers.
    Lehnert M
    Ann Oncol; 1993 Jan; 4(1):11-3. PubMed ID: 8435355
    [No Abstract]   [Full Text] [Related]  

  • 40. Targeting HER2 Positive Breast Cancer with Chemopreventive Agents.
    Wahler J; Suh N
    Curr Pharmacol Rep; 2015 Oct; 1(5):324-335. PubMed ID: 26442201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.